GHRP-2 Protocols: A Research-Based Overview (Not a Recommendation)

GHRP-2 at a glance:

• Drug class: Growth hormone secretagogue
• Route: subcutaneous injection (peptides) or oral (small molecules)
• Typical frequency: once daily to once weekly depending on agent
• Half-life: varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)

GHRP-2 cycling discussions trace to bodybuilding-era practice and receptor-desensitization theory. The evidence base supporting any specific cycle is thin to nonexistent.

What "Cycle" Means in Peptide Discussions

In research-peptide and GHS communities, a "cycle" usually refers to a defined period of administration (often 8-12 weeks) followed by a break. The rationale draws on receptor desensitization theory and historical bodybuilding practice.

For GHRP-2: any cycling pattern outside the labeled indication is off-label and not evidence-based.

Published Research Dosing

FDA-approved agents have specific labeled dosing. Research-only GHS peptides have no validated human dosing.

When peptides are studied in research, the doses come from animal-to-human translation, prior pharmacokinetic data, and trial designs that can't be assumed to apply to individual self-administration.

What Researchers Actually Do

In the published research literature on GHRP-2:

• Doses are typically expressed in mcg/kg or fixed mg amounts
• Administration routes match what was tested for safety
• Duration is bounded by the trial protocol (often 8-12 weeks)
• Outcome measurement is structured and pre-specified

These are not personal protocols; they're trial designs.

Why We Don't Publish Self-Administration Protocols

Three reasons:

1. Compound purity and identity are not verifiable for material from grey-market sources
2. Individual response to non-FDA-approved compounds is not characterized at the population level
3. Liability and safety realities make specific instructions inappropriate for an informational site

For GHRP-2 specifically, the evidence base is too thin to support specific guidance.

What to Do Instead

If you're researching GHRP-2 because of a specific health goal, the more productive path is usually:

• Identify the underlying issue (musculoskeletal, metabolic, etc.)
• Look at FDA-approved options that address it
• Talk to a clinician with relevant expertise
• Consider research-peptide options only as a last resort, with clear understanding of unknowns

Risks to Understand

• impaired glucose tolerance
• carpal tunnel syndrome
• theoretical IGF-1-mediated effects on tumor growth

These are compound to the risks of unregulated supply (purity, contamination, dosing accuracy).

Bottom Line

We don't publish GHRP-2 cycling protocols because the evidence doesn't support specific recommendations. The honest answer is: research dosing exists, but it's not personal advice.

Frequently Asked Questions

Related Reading

• GHRP-2: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• GHRP-2 Side Effects in 2026: Real Reports, Real Solutions
• Real GHRP-2 Results: What 6 and 12 Months Actually Look Like
• GHRP-2 Cost in 2026: What You'll Actually Pay (Real Numbers)
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.
• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.
• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.

This page is informational only and is not medical advice or a recommendation for self-administration of any compound.